MARKET

PTCHF

PTCHF

Puretech Health
OTCPK
1.700
NaN%
Closed 09:30 12/05 EST
OPEN
--
PREV CLOSE
1.700
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
2.200
52 WEEK LOW
1.520
MARKET CAP
410.86M
P/E (TTM)
8.20
1D
5D
1M
3M
1Y
5Y
1D
PureTech’s Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
Barchart · 1d ago
PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group
Barchart · 10/22 01:00
PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF
Barchart · 09/29 01:00
Weekly Report: what happened at PTCHF last week (0908-0912)?
Weekly Report · 09/15 11:21
Weekly Report: what happened at PTCHF last week (0901-0905)?
Weekly Report · 09/08 11:24
Weekly Report: what happened at PTCHF last week (0825-0829)?
Weekly Report · 09/01 11:18
PureTech Health plc reports 1H results
Seeking Alpha · 08/28 08:33
PureTech Health plc – Half-Year Report
Barchart · 08/28 01:00
More
About PTCHF
PureTech Health plc is a clinical-stage company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.

Webull offers Puretech Health PLC stock information, including OTCPK: PTCHF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTCHF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PTCHF stock methods without spending real money on the virtual paper trading platform.